REVIEW article
Front. Pharmacol.
Sec. Neuropharmacology
Volume 16 - 2025 | doi: 10.3389/fphar.2025.1652296
This article is part of the Research TopicAdvances in Neuropharmacological Therapies: From Molecular Discoveries to Personalized Clinical ApplicationsView all articles
The Mechanism and Therapeutic Potential of SIRT3 in Central Nervous System Diseases: A Review
Provisionally accepted
- 1Changchun University of Chinese Medicine, Changchun, China
- 2Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China
- 3Beijing University of Chinese Medicine, Beijing, China
- 4Affiliated Hospital to Changchun University of Chinese Medicine, Changchun, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Sirtuin-3 (SIRT3) is a mitochondrial deacetylase highly expressed in the nervous system, known to regulate mitochondrial homeostasis, energy metabolism, neuroinflammation, apoptosis, and oxidative stress, suggesting its potential neuroprotective role in central nervous system (CNS) disorders. Recent studies indicated that SIRT3 improves neuronal survival by reducing oxidative damage, alleviating neuroinflammation, and modulating autophagy. Therefore, it is imperative to conduct more in-depth and extensive investigations into the mechanisms underlying SIRT3 in central nervous system disorders. This review summarized current research advances on SIRT3, including its fundamental molecular structure, key downstream targets, and mechanisms of action in certain CNS diseases. It further analyzed the potential pharmacological mechanisms of several SIRT3 agonists and explored their therapeutic value in improving CNS disorders. Based on existing evidence, SIRT3 emerges as a promising therapeutic target, offering novel strategies for treating neurological diseases.
Keywords: sirt3, Silent information regulator 3, sirtuin-3, Central Nervous System Diseases, Mitochondrial function, Therapeutic potential
Received: 23 Jun 2025; Accepted: 18 Aug 2025.
Copyright: © 2025 Hong, Wei, Wang, Lv, Dong and Huang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Xinglu Dong, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China
Xiaowei Huang, Affiliated Hospital to Changchun University of Chinese Medicine, Changchun, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.